Hypothesis

Age-related decline in butyrate-producing gut microbes reduces circulating butyrate, removing an endogenous brake on histone deacetylase 2 (HDAC2) activity in hippocampal neurons. This unleashes HDAC2-mediated synaptic over-consolidation via L-type VGCC-dependent LTP, producing cognitive rigidity mistaken for decay. Restoring butyrate will reinstate HDAC inhibition, shift LTP back to NMDA-dependent specificity, and rescue flexible cognition.

Novel Mechanistic Insight

Butyrate not only inhibits HDACs directly; it also activates the G‑protein‑coupled receptor GPR109A on microglia, prompting an anti‑inflammatory phenotype that reduces NF‑κB‑driven HDAC2 transcription in neurons. Thus, gut‑derived butyrate exerts a dual epigenetic control: neuronal HDAC inhibition and microglial suppression of HDAC2 expression. Loss of butyrate therefore amplifies HDAC2 through both decreased enzymatic inhibition and increased gene expression, creating a feed‑forward loop of synaptic stabilization.

Testable Predictions

1. Aged mice with low fecal butyrate will show elevated hippocampal HDAC2 protein, increased L‑type VGCC‑dependent LTP, and impaired performance on reversal‑learning tasks.
2. Oral supplementation with a butyrate‑producing probiotic (e.g., Clostridium butyricum) or sodium butyrate will normalize fecal butyrate, decrease hippocampal HDAC2 activity, shift LTP toward NMDA‑dependence, and improve reversal learning.
3. Microglial‑specific GPR109A knockout will block the cognitive benefits of butyrate supplementation despite restored neuronal HDAC inhibition, confirming the microglial pathway.

Experimental Design (Falsifiable)

• Subjects: 24‑month‑old C57BL/6J mice (n=10 per group).
• Groups: (a) Vehicle control, (b) Sodium butyrate (300 mM in drinking water), (c) C. butyricum probiotic (10⁹ CFU/day), (d) Butyrate + microglial GPR109A antagonist, (e) Young adult (3‑month) baseline.
• Measurements (after 4 weeks): fecal butyrate (GC‑MS), hippocampal HDAC2 Western blot and activity assay, ex vivo slice electrophysiology (NMDA‑ vs L‑type VGCC‑LTP), reversal learning in the Morris water maze, microglial Iba1 and GPR109A immunostaining.
• Falsification: If butyrate treatment fails to reduce HDAC2 activity or shift LTP phenotype, or if cognitive improvement occurs without changes in HDAC2/LTP, the hypothesis is refuted.

Broader Implications

Demonstrating that gut‑derived butyrate governs an epigenetic brake on synaptic stability would reframe cognitive aging as a reversible metabolic‑immune dysregulation, opening therapeutic avenues that target the microbiome rather than attempting to reconstitute youthful neuronal circuitry.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC2928699/ [2] https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2015.00208/full [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC7374892/ [4] https://todayspractitioner.com/longevity/unraveling-the-role-of-butyrate-in-cellular-health-and-aging/ [5] https://insight.jci.org/articles/view/168443 [6] https://academic.oup.com/innovateage/article/7/Supplement_1/931/7490788